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Background and Objectives: Current literature may overestimate the risk of nodal
metastasis from thin melanoma due to reporting of data only from lesions treated with
SLNB. Our objective was to define the natural history of thin melanoma, assessing the
likelihood of nodal disease, in order to guide selection for SLNB.
Methods: Retrospective review. The primary outcome was the rate of nodal disease.
Clinicopathologic factors were evaluated to find associations with nodal disease.
Results: Five hundred and twelve lesions, follow up available for 488 (median: 48
months). Lesions treated withWLE/SLNB compared toWLE alone weremore likely to
have high-risk features. The rate of nodal disease was higher in the WLE/SLNB group
(24 positive SLNB, five false-negative SLNB with nodal recurrence: 10.2%) compared
to WLE alone (four nodal recurrences: 2.0%). Univariate analysis showed age ≤45,
Breslow depth ≥0.85mm, mitotic rate >1mm2, and ulceration were associated with
nodal disease. Multivariate analysis confirmed the association of age ≤45 and
ulceration.
Conclusions: SLNB for melanoma 0.75-0.99mm should be considered in patients age
≤45, Breslow depth ≥0.85mm, mitotic rate >1mm2, and/or with ulceration. Thin
melanoma <0.85mm without high-risk features may be treated with WLE alone.
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1 | INTRODUCTION
Thin melanoma is defined as invasive melanoma with Breslow depth
<1.0 mm and generally has an excellent prognosis.1,2 While the risk of
nodal and distant metastasis from thin melanoma is low, optimizing
treatment is important as an estimated 40 000 new cases of thin
melanoma are diagnosed annually in the United States alone,
representing the majority of new cases.3
Robust data support the utility of sentinel lymph node biopsy
(SLNB) for melanoma ≥1.0mmBreslow depth.4–9 Data regarding SLNB
for thinmelanoma (<1.0mm), in contrast, is limited by retrospective and
often conflicting reports ofwhat constitutes high-risk features for nodal
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metastasis and thus selection criteria for performance of SLNB.10,11 The
2016 National Comprehensive Cancer Network (NCCN) guidelines
recommend “discussion and consideration” of SLNB for melanoma
0.76-1.0mm, particularly for lesions with high-risk histologic features.8
High-risk features can include increasing Breslow depth, ulceration,
lymphovascular invasion, and a high mitotic rate.8 Other reports have
included young age, positive deep margin on biopsy, Clark level IV/V,
vertical growth phase, regression, and lack of tumor infiltrating
lymphocytes as adverse prognosticators.12–25
The purpose of our study was to define the natural history of thin
melanoma 0.75-0.99mm, identify features associated with a higher
risk for regional nodal disease, and thus determine patient selection
criteria for SLNB in the future. We evaluated a cohort of consecutive
patients with melanoma 0.75-0.99mm treated at a single institution
concordant with NCCN guidelines with either WLE plus SLNB orWLE
alone. By analyzing all patients, rather than only patients treated with
WLE plus SLNB as in the majority of reports in the literature, we aimed
to more completely define the natural history through recurrence
outcomes and to identify high-risk features associated with regional
nodal disease not simply SLN positivity.
2 | MATERIALS AND METHODS
Study approval was granted by the University of Michigan Medical
School Institutional Review Board for Human Subject Research. Our
prospectively collected database was queried for melanoma Breslow
depth 0.75-0.99mm, diagnosed and treated at the University of
Michigan between January, 2005 and July, 2015. Cases were excluded
if subsequent excisional biopsy orWLE specimen containedmelanoma
≥1.0 mm or if the patient had a known second primary Breslow depth
≥1.0 mm. Demographic, clinical, and outcome measures were con-
firmed via the electronic medical record and by phone contact with the
patient or referring physician’s office. The follow up time for each
patient was calculated as the difference between initial biopsy date
and date of last contact, with the median follow-up time reported. The
follow up period ended April 15, 2016.
All patients were seen in theMultidisciplinaryMelanoma Clinic for
consultation and discussion regarding melanoma treatment. SLNB
was considered for all patients based on Breslow depth 0.75-0.99mm,
concordant with NCCN guidelines.26 The presence of additional
features considered higher risk for occult regional lymph node
metastasis based on current literature included: increasing Breslow
depth, ulceration, lymphovascular invasion, high(er) mitotic rate, and
young(er) age, regression (defined as partial or complete replacement
of melanoma with a variable host response, as previously described),27
and positive deepmargin on biopsy. Patientswere treatedwithWLE or
WLE plus SLNB based on the discussion of potential risks and benefits
of the surgery, risk of nodal metastasis, and individual patient
preference.
Surgery was performed by 32 different surgeons from the
University of Michigan Departments/Divisions of Dermatology,
Surgical Oncology, Plastic Surgery, Otolaryngology-Head and Neck
Surgery, Gynecology Oncology (one case), and Pediatric Surgery (one
case). Those treated with WLE plus SLNB were treated by one of 14
surgeons who routinely perform SLNB, according to our standard
practices.6,8 Patients treated with WLE only usually had procedures
performed with local anesthesia in a treatment room with a 1 cm
margin.8 All WLE specimens were processed using formalin-fixed
permanent sections. SLNs were formalin fixed, serially sectioned and
evaluated with hematoxylin and eosin, S100, and Melan A immunos-
tains, as previously described.28 All specimens were interpreted by
dermatopathologists with expertise in melanoma and SLN evaluation.
Patients with a positive SLN(s) were counseled regarding
completion lymph node dissection (CLND) as the standard of care
following identification of a positive SLN. Adjuvant therapy was
considered following consultation with attending physicians from
Medical Oncology with expertise in melanoma. Adjuvant and systemic
therapy options did change during the study time frame due to the
development of new therapies.29
3 | STATISTICAL METHOD
The outcomes evaluated were: SLNB positivity rate, local recurrence,
in-transit recurrence, regional nodal recurrence, distant recurrence,
and death from melanoma. Descriptive statistics were calculated for
each clinical and pathological variable (frequency/percentage for a
categorical variable, mean/standard deviation for a continuous
variable). The events of interest were performance of SLNB
(yes/no) and presence of nodal disease (defined as either a positive
SLNB or nodal recurrence in the follow up period, regardless of
SLNB status). To determine an association between any factor and
the event of interest, a logistic regression model was used. To
appropriately control for potential confounding clinical and patho-
logic variables when explaining nodal disease, a multivariate logistic
regression model was used. All variables were considered in the
model, including the two-way interactions (age × mitotic rate,
age × Breslow depth, and age × ulceration). A stepwise variable
selection procedure was used to select important variables to be
included in the final logistic regression model (a significance level of
0.3 was used to allow a variable into the model, and a significance
level of 0.35 was used for a variable to stay in the model). The final
model included age, Breslow depth, ulceration, and mitotic rate (no
interaction was found to be statistically significant). The parameter
estimates from the model, the P value from the Wald chi-square test
for the significance of the parameter, the odds ratio (OR), and a 95%
Wald-based confidence interval (95%CI) for the OR were reported.
Significance was determined if P < 0.05. For the univariate and
multivariate analyses of features associated with the presence of
nodal disease, age and Breslow depth were analyzed as categorical
variables for consideration as potential patient selection criteria for
SLNB in clinical practice guidelines. Consistent with current
literature and our practice guidelines, categorical age was defined
as ≤45 and >45 years. Similarly, and with consideration of the new
AJCC definition of T1a/b lesions based on a 0.8 mm cutpoint
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(to define tumor thickness measurements at the “tenth” rather than
“hundredth” digit), categorical Breslow depth was defined as <0.85
and ≥0.85 mm to allow for classifying as 0.8 or ≥0.9 mm,
respectively. All analyses were conducted using SAS (version 9.4,
SAS Institute, Cary, NC).
4 | RESULTS
Based on initial biopsy, 552 thin melanomas with Breslow depth
0.75-0.99mm were identified. Forty lesions were excluded after
subsequent excisional biopsy orWLE demonstrated depth ≥1.0 mm. In
24/40 (60%), residual tumor was noted at the consultation visit and
deeper melanoma was suspected. The median final Breslow depth of
these 40 lesions was 2.07mm.
In the study cohort, there were 510 patients with 512 lesions
Breslow depth 0.75-0.99mm. The mean patient age was 56.7 years
(range 16-92). Two hundred twenty-six (44.3%) were women, 284
(55.7%) were men. The majority of lesions were located on the
extremities (238/512, 46.5%) and trunk (178/512, 34.8%) with a
smaller number on the head or neck (96/512, 18.8%). The predominant
histologic subtype was superficial spreading (405/512, 79.1%). The
other main histologic subtypes included lentigo maligna melanoma
(32/512, 6.3%), unclassified type (26/512, 5.1%), nodular (20/512,
3.9%), nevoid (12/512, 2.3%), and spitzoid (9/512, 1.8%).
Two hundred ninety-five (57.6%) tumors were treated with WLE
plus SLNB. The remaining 217 (42.4%) tumors were treated with
WLE alone. Comparison of patient and lesion characteristics for the
WLE plus SLNB versus WLE groups showed that younger age
(continuous) (P < 0.001), gender (F vs M) (P < 0.001), Breslow depth
(continuous) (P < 0.0001), mitotic rate ≥1mm2 (P < 0.001), positive
deep margin on biopsy (P = 0.019), ulceration (P = 0.007), and
regression (P = 0.006) were associated with performance of SLNB
(Table 1).
The SLN identification rate was 98.3% (290/295). The median
number of SLNs removed per patient was 2. Two hundred
fifty-four patients (87.6%) had SLNs removed from only one
nodal basin, 34 lesions (11.7%) mapped to two basins, and two
lesions (0.7%) mapped to three unique nodal basins. The rate of
SLNB positivity was 8.1% (24/295). Twenty-one patients (87.5%)
had one positive SLN, one patient (4.2%) had two, and two
patients (8.3%) had three positive SLNs. No extracapsular
extension was identified. Nineteen (79.2%) of 24 patients with
a positive SLNB underwent CLND. Three patients declined and
TABLE 1 Factors associated with performance of SLNB in patients with thin (0.75-0.99mm) melanoma
SLNB performed Univariate analysis
Characteristics Yes n = 295 No n = 217 P OR 95%CI
Age (continuous, +1 year) Mean <0.001 0.946 0.933 0.959
52 63.2
Gender (F vs M) <0.001 2.054 1.43 2.949
F 152 74
M 143 143
Breslow depth (continuous, +0.1 mm) Mean <0.0001 3.09 2.25 4.29
0.88 0.84
Mitotic rate (≥1 vs 0mm2)a <0.001 3.91 2.673 5.719
≥1mm2 226 98
0mm2 69 117
Positive deep margin (yes vs no)a 0.019 1.684 1.089 2.602
Yes 78 38
No 217 178
Ulceration (present vs absent)a 0.007 15.667 2.089 117.493
Present 20 1
Absent 274 215
Regression (present vs absent) 0.006 0.57 0.38 0.85
Present 61 68
Absent 234 149
Angiolymphatic invasion (present vs absent)a 0.12 3.37 0.72 15.7
Present 9 2
Absent 286 214
aMitotic rate and ulceration unknown in 2 pts, Deep margin status and angiolymphatic invasion status unknown in 1 pt.
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two died prior to CLND from unrelated causes (acute cerebro-
vascular accident and pyelonephritis). Of the 19 who had CLND,
no additional positive nodes were identified.
Following CLND, four patients were treated with adjuvant high-
dose interferon therapy. Two discontinued treatment due to side
effects (after 2 and 3months, respectively). Another patient entered an
adjuvant therapy clinical trial (Dabrafenib 150mg p.o. twice
daily + Trametinib 2mg p.o. daily vs placebo).
Twenty-four patients (4.7%) were lost to follow up after the
immediate post-operative period (12 WLE, 12 WLE plus SLNB). The
median follow-up time for the remaining 486 patients (488 tumors:
205 WLE, 283 WLE plus SLNB) was 48 months. The treatment and
outcomes of the cohort are represented in Fig. 1.
Two tumors (0.4%) located on the head and neck (one lentigo
maligna melanoma, one superficial spreading type) locally recurred
after 15 and 28 months, respectively, after WLE only. Two patients
(0.4%) developed in-transit recurrence. One patient (treated withWLE
alone) was diagnosed concurrently with in-transit and nodal
recurrence. The other patient (treatedwithWLE plus SLNB) developed
in-transit recurrence at 52 months and nodal disease at 53 months.
Nine (1.8%) regional nodal basin recurrences developed; four in
patients treated withWLE alone and five in patients treated withWLE
plus negative SLNB. Thus, the false negative rate (FNR)was 17.2% (five
false negative SLNB/[five false negative SLNB + 24 true positive
SLNB]. All five patients with a negative SLNB who developed regional
nodal recurrence failed in the same basin as the SLNB. For the two
cases of false-negative SLNB on the head and neck, one patient was
treated prior to routine use of single-photon emission computed
tomography with CT (SPECT/CT) and, therefore, did not have
SPECT/CT imaging as part of the SLNB procedure. Two patients
developed in-transit recurrence in addition to nodal recurrence (one
WLE alone [concurrent in-transit and nodal recurrence]), oneWLE plus
SLNB [in-transit recurrence one month before nodal recurrence]). The
median time to nodal recurrence was 16 months (range: 6-53). No
nodal recurrences occurred in patients who had a positive SLNB
(median follow up time for this subset of patients was 32.5 months),
including those who did not have CLND. The patient and lesion
characteristics for cases of nodal recurrence are provided in Table 2.
In total, 33 (6.8%) patients ultimately developed nodal metastases
from thin melanoma (24 found with positive SLNB and nine nodal
recurrences). Regional nodal diseasewas themost common first site of
disease identified beyond the primary site (32 [one with concurrent
in-transit disease and one with concurrent distant disease] of 35
patients with stage III/IV disease). Univariate analysis showed that age
≤45 (P = 0.027), Breslow depth ≥0.85mm (P = 0.04), mitotic rate
>1mm2 (P = 0.031), and ulceration (P = 0.001) were significantly
associated with nodal disease. Microsatellitosis was not present in
any tumor. Multivariate analysis was performed as previously
described. The final model considered age (>45 vs ≤45), Breslow
depth (≥0.85 vs <0.85mm), mitotic rate (>1 vs ≤1mm2), and ulceration
(present vs absent); only age ≤45 (>45 vs ≤45: P = 0.007, OR 0.336,
95%CI 0.152-0.74) and ulceration (present vs absent: P = 0.003, OR
5.932, 95%CI 1.805-19.496) were statistically significant independent
factors associated with nodal disease (Table 3).
Eight (1.6%) distant recurrences developed (the median time to
distant recurrence was 28.5 months, range 10-74), resulting in seven
deaths. Four lesionswere treatedwithWLE and fourwere treatedwith
WLE plus negative SLNB. Nodal recurrence preceded distant
FIGURE 1 Outcome measures. This figure shows outcome measures including: local recurrence, in-transit recurrence, nodal metastasis,
distant metastasis, and death from melanoma for 486 patients with 488 primary lesions 0.75-0.99mm Breslow depth after a median follow
up time of 48 months.
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metastasis in five cases (62.5%), by a median time of 12months (range:
4-21). One patient developed nodal recurrence and distant metastasis
concurrently after 10 months (WLE and false-negative SLNB). Two
patients developed distant metastatic disease without nodal recur-
rence (both were treated with WLE alone). One patient with distant
metastasis remains alive (78months fromprimary diagnosis, 23months
from initiation of systemic therapy). No distant recurrences developed
in patients with a positive SLNB (median follow up time for this subset
of patients was 32.5 months).
5 | DISCUSSION
The intent of this study was to use SLNB data and recurrence
outcomes to define the natural history of thin melanoma
(0.75-0.99mm) in terms of disease recurrence and risk of nodal
metastases with and without SLNB, and to identify factors associated
with nodal disease that could be useful as patient selection criteria for
SLNB. This studywas intentionally designed to include patients treated
with WLE plus SLNB and patients treated with WLE alone and differs
from the majority of outcome studies of thin melanoma that only
evaluate patients undergoing WLE plus SLNB. As patients are
frequently selected for SLNB because of higher risk features for
nodal metastases, these prior studies are inherently biased and may
overestimate the likelihood of nodal metastases from thin melanoma.
Outcomes from this study showed that regional nodal disease was
the most common first site of disease identified beyond the primary
site (24 patients with positive SLNB, eight patients with delayed nodal
recurrence [one with concurrent in-transit recurrence, one with
concurrent distant recurrence]). Five of the eight patients with nodal
recurrence subsequently died of distant disease. Only two patients
developed distant disease as the first site of disease beyond the
primary site and both patients died from melanoma.
In our cohort of all patients with thin melanoma, Breslow depth
0.75-0.99mm, the overall nodal metastatic rate was 6.8% (33 nodal
metastases/488 tumors). The nodal metastatic rate observed in
patients treated with WLE plus SLNB (24 positive SLNB, five false-
negative SLNB with nodal recurrence) was 10.2%. In patients treated
with WLE alone, the rate of nodal disease was 2.0% (four nodal
recurrences). Compared to patients treated with WLE only, patients
who underwent SLNB were more likely to be younger, female, have a
deeper Breslow depth, mitotic rate ≥1mm2, positive deep margin,
ulceration, and/or regression. Notably, all four of the patients treated
with WLE alone that had nodal recurrence had primary lesions with
Breslow depth ≥0.8 mm (0.91, 0.9, 0.9, and 0.8 mm) and two patients
were <45 years old (43 and 44) (Table 2).
The higher rate of nodal disease in the SLNB group may be, at
least partly, attributable to lead-time bias and a relatively limited
follow up time. Thin melanoma has been reported to recur long
after initial treatment, in some cases >10 years after diagnosis.15 It
is likely that additional recurrences will develop in all groups,
including those patients with a negative SLNB and those treated
with WLE alone. Continued follow-up of our cohort beyond the
reported median 48 months will provide additional valuable
information.
Interestingly, the largest meta-analysis (60 studies, 10 928
patients) to evaluate SLNB for thin melanoma was published in
2016 and included only those who had SLNB. Breslow depth
TABLE 2 Patient and lesion characteristics in cases of nodal recurrence
Treatment Age Gender Site
Melanoma
type
Breslow
depth
(mm)
Mitotic
rate
(#/mm2) Ulceration Regression ALIa PNIa
Time to
recurrence
(months)
WLE + FN
SLNBa
59 M Scalp Superficial
spreading
0.80 2 No Yes No No 11
WLE + FN
SLNB
31 F Foot Superficial
spreading
0.86 2 No No No No 53
WLE + FN
SLNB
43 M Leg Superficial
spreading
0.90 3 No Yes No No 17
WLE + FN
SLNB
42 F Neck Superficial
spreading
0.78 1 Yes No Yes No 7
WLE + FN
SLNB
44 F Foot Superficial
spreading
0.90 1 No No No No 10
WLE 70 M Neck Superficial
spreading
0.91 0 No No No No 6
WLE 67 F Arm Nodular 0.90 0 No No No No 16
WLE 44 M Trunk Superficial
spreading
0.80 0 No No No No 40
WLE 43 M Trunk Spitzoid 0.90 0 No No No No 39
aWLE, wide local excision; FN SLNB, false-negative sentinel lymph node biopsy; ALI, angiolymphatic invasion; PNI, perineural invasion.
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≥0.75mm (adjusted odds ratio (AOR) 1.9; 95%CI 1.08-3.340), Clark
level IV/V (AOR 2.24; 95%CI 1.23-4.08), mitotic rate ≥1mm2 (AOR
6.64; 95%CI 2.77-15.88), and presence of microsatellites (unadjusted
OR 6.94; 95%CI 2.13-22.60) were associated with a positive SLNB.
The authors concluded that patients with melanoma ≥0.75mm should
be offered SLNB, based on a SLNBpositivity likelihood of 8.8%. If other
high-risk features are present, the rate of SLNB positivity may be even
higher.11
Univariate analysis of our entire cohort, including patients treated
withWLE alone, showed age ≤45, Breslow depth ≥0.85mm, mitotic rate
>1mm2, and ulceration to be significantly associated with nodal disease
(positive SLNBor nodal recurrence in the followupperiod) supporting the
useof these risk featuresas selectioncriteria forSLNB inpatientswith thin
melanoma 0.75-0.99mm. This analysis is more clinically relevant than
prior reports because it uses the entire population of patients with thin
melanomarather than just thesubsetof thoseselected forSLNB.Ourdata
would suggest that SLNB be considered for AJCC 8th Edition30 T1b
lesions 0.8-1.0mm with any of the following high-risk features: age ≤45,
Breslow depth ≥0.85mm (rounded to 0.9mm for the AJCC 8th Edition),
mitotic rate >1mm2, and/or ulceration.
TABLE 3 Factors associated with nodal disease in patients with thin (0.75-0.99mm) melanoma
Nodal disease Univariate analysis
Characteristics Yes No P OR 95%CI
Age (>45 vs ≤45 years) 0.027 0.431 0.205 0.91
>45 21 365
≤45 12 90
Gender (F vs M) 0.36 1.392 0.686 2.823
F 17 197
M 16 258
Breslow depth (≥0.85 vs <0.85mm) 0.04 2.43 1.03 5.72
≥0.85mm 26 275
<0.85mm 7 180
Mitotic rate (≥1 vs 0mm2) 0.14 1.842 0.812 4.177
≥1mm2 25 285
0mm2 8 168
Mitotic rate (>1 vs ≤1mm2) 0.031 2.2 1.076 4.499
>1mm2 15 125
≤1mm2 18 330
Positive deep margin (yes vs no)a 0.8 0.895 0.378 2.12
Yes 7 105
No 26 349
Ulceration (present vs absent)a 0.001 6.282 2.087 18.91
Present 5 13
Absent 27 441
Regression (present vs absent) 0.18 0.51 0.19 1.35
Present 5 118
Absent 28 337
Angiolymphatic invasion (present vs absent)a 0.68 1.55 0.19 12.58
Present 1 9
Absent 32 445
Multivariate analysis
Characteristic P Estimate OR 95%CI
Age (>45 vs ≤45 years) 0.007 −0.5455 0.336 0.152 0.74
Breslow depth (≥0.85 vs <0.85mm) 0.12 0.3532 2.027 0.838 4.899
Mitotic rate (>1 vs ≤1mm2) 0.14 0.2919 1.793 0.824 3.902
Ulceration (present vs absent) 0.003 0.8902 5.932 1.805 19.496
aUlceration status unknown in 2 pts, Deep margin status and angiolymphatic invasion unknown in 1 pt.
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In thin melanoma there is conflicting evidence regarding the
prognostic significance of a positive SLN.2,15,23,31 In our patients
with a positive SLNB, no recurrences were noted in the follow up
period. It is possible that the follow up time is insufficient to capture
long-term events. However, this observation also raises the
possibility that SLNB-directed early intervention may provide a
therapeutic benefit with improved outcomes in thin melanoma
similar to that demonstrated for intermediate depth melanoma in the
Multicenter Selective Lymphadenectomy-I (MSLT-I) trial.9 In our
patients with a positive SLNB who underwent CLND (19/24
patients), no additional positive nodes were identified. Results
from the Multicenter Selective Lymphadenectomy Trial-II and
adjuvant therapy trials may lead to changes in the management of
SLNB positive patients in the future.32
Our study population may be subject to potential selection bias
based on patient referral to a tertiary cancer center. However, our
Multidisciplinary Melanoma program evaluates and treats nearly 80%
of all melanoma cases in our state. Additional limitations include the
retrospective design and relatively limited follow up time, though a
median follow up of 48 months is equivalent to or longer than many
comparable studies reported in contemporary literature.
6 | CONCLUSIONS
Patients with thin melanoma can and do develop regional lymph node
and distant disease and may die from melanoma. The eight distant
recurrences and seven deaths serve as a reminder that although thin
melanoma has an excellent prognosis, some patients will have an
adverse outcome. This study supports that regional nodal disease is the
most common first site of spread detected beyond the primary site in
the natural history of thin melanoma 0.75-0.99mm. Furthermore, this
study supports that a subset of these thin melanomas have a sufficient
risk to consider nodal staging with SLNB. Specifically, SLNB should be
strongly considered for thin melanoma 0.75-0.99mm in the setting of
patient age ≤45 years, Breslow depth ≥0.85mm, mitotic rate >1mm2,
and/or ulceration of the primary lesion. Thin melanoma <0.85mm
(to be defined as ≤0.8 mm in the 8th edition of the AJCC) without
additional high-risk features likely has a low rate of nodal metastases
and therefore may be treated with WLE alone.
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